P487 Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease

Autor:	K Pudilova, M Kolar, D Duricova, K Malickova, V Hruba, N Machkova, R Vanickova, K Mitrova, M Lukas, M Vasatko, M Bortlik
Rok vydání:	2019
Předmět:	medicine.medical_specialty business.industry Gastroenterology General Medicine medicine.disease Trough (economics) Inflammatory bowel disease Vedolizumab Internal medicine medicine In patient business medicine.drug
Zdroj:	Journal of Crohn's and Colitis. 13:S355-S356
ISSN:	1876-4479 1873-9946
DOI:	10.1093/ecco-jcc/jjy222.611
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::752e85dd2d9edc15c7112b6aa40b4697 https://doi.org/10.1093/ecco-jcc/jjy222.611 Zobrazit plný text záznamu